slc25a47a Antibody

What is SLC25A47 and why is it significant for research?

SLC25A47 (Solute Carrier Family 25 Member 47) is a mitochondrial carrier protein with significant research importance in liver metabolism and disease. This protein consists of 308 amino acid residues with a molecular mass of approximately 33.4 kDa in humans . SLC25A47 functions as an uncoupling protein that may catalyze the physiological "proton leak" in liver mitochondria, making it particularly relevant for research on hepatic energy metabolism . Recent evidence suggests it serves as a mitochondrial NAD+ transporter and plays critical roles in lipid metabolism regulation . The protein is primarily expressed in the liver, and its dysregulation has been implicated in metabolic disorders and hepatocellular carcinoma development, as demonstrated by spontaneous HCC occurrence in Slc25a47-knockout mice .

What types of SLC25A47 antibodies are available for research?

Research-grade SLC25A47 antibodies are available in several formats to accommodate different experimental needs. The most common types include:

• Polyclonal antibodies: Generated in hosts such as goat, targeting specific epitopes like amino acids 242-254 (sequence KSRLQADGQGQRR)

• Unconjugated antibodies: Available from multiple suppliers for applications requiring secondary detection systems

• Species-specific antibodies: Primarily reactive against human SLC25A47, though some cross-reactivity with other species may exist

The selection of specific antibody types should be guided by the intended application and experimental design requirements.

What are the main applications for SLC25A47 antibodies in research?

SLC25A47 antibodies have demonstrated utility in several key research applications:

• Immunohistochemistry (IHC): Particularly effective for detecting SLC25A47 in paraffin-embedded liver tissues, with staining observed in nucleoli of select hepatocytes

• Enzyme-Linked Immunosorbent Assay (ELISA): Used for quantitative detection of SLC25A47 in various sample types

• Western blotting: Though preliminary experiments have shown bands at approximately 22 kDa (differing from the expected 33.4 kDa), this application requires further optimization

• Research on metabolic diseases: Particularly valuable for studying lipid metabolism disorders and hepatic disease models

How can SLC25A47 antibodies be effectively used to study mitochondrial transport function?

When designing experiments to investigate SLC25A47's role in mitochondrial transport:

• Isolation protocol optimization: Employ mitochondrial isolation techniques that preserve membrane integrity to accurately assess transport functions.

• Functional assays: Combine antibody-based detection with substrate uptake assays, similar to the NAD+ uptake measurements performed in isolated mitochondria from wild-type and Slc25a47-KO mice .

• Complementary approaches: Use SLC25A47 antibodies in conjunction with techniques like isotope tracing experiments (e.g., with [U-13C] Glucose) to comprehensively assess metabolic pathways affected by SLC25A47 function or deficiency .

• Control selection: Include appropriate controls such as mitochondria from Slc25a47-knockout mice and Slc25a47-overexpressing models to establish specificity of transport phenotypes .

These methodological considerations ensure reliable assessment of SLC25A47's role in mitochondrial substrate transport and metabolism.

How should researchers interpret discrepancies in detected molecular weights for SLC25A47?

The observed discrepancy between the expected molecular weight (33.4 kDa) and experimentally detected bands (approximately 22 kDa) in Western blotting warrants careful consideration:

• Post-translational modifications: Investigate whether SLC25A47 undergoes proteolytic processing in mitochondria, similar to other mitochondrial carriers.

• Isoform detection: Consider the possibility that the antibody may be detecting one of the reported isoforms rather than the canonical protein .

• Validation approaches:

  • Compare results using multiple antibodies targeting different epitopes

  • Confirm specificity using samples from Slc25a47-knockout models as negative controls

  • Employ mass spectrometry to confirm protein identity of detected bands

• Sample preparation effects: Assess whether mitochondrial protein extraction methods affect detection of the full-length protein.

Understanding these discrepancies is crucial for accurate interpretation of experimental results and avoiding misattribution of signals to SLC25A47.

What considerations should be made when studying SLC25A47 in hepatocellular carcinoma models?

Research on SLC25A47's role in hepatocellular carcinoma requires careful experimental design:

• Model selection: Consider that Slc25a47-KO mice spontaneously develop HCC at approximately 20 months of age, making them valuable models for long-term carcinogenesis studies .

• Biomarker correlation: Combine SLC25A47 antibody staining with established HCC markers like Ki67 to correlate expression patterns with disease progression .

• Metabolic profiling: Integrate antibody-based detection with lipid accumulation analysis, as evidenced by the observation that Slc25a47 deficiency imbalances lipid metabolism homeostasis in hepatocytes .

• Pathway analysis: Investigate connections between SLC25A47 and key metabolic regulators like AMPK and SIRT3, as these relationships appear important in the context of HCC development .

• Therapeutic intervention assessment: Use models like DEN-induced HCC in Slc25a47-KO mice treated with rapamycin to evaluate therapeutic interventions .

These considerations enable more comprehensive investigation of SLC25A47's potential roles in liver cancer development and progression.

What are the optimal protocols for immunohistochemical detection of SLC25A47 in liver tissues?

For successful immunohistochemical detection of SLC25A47 in liver tissues:

• Sample preparation:

  • Use paraffin-embedded human liver tissues sectioned at 4-5 μm thickness

  • Perform antigen retrieval using citrate buffer (pH 6.0) or as recommended for the specific antibody

• Antibody concentration and incubation:

  • Use a recommended concentration of 2.5 μg/mL for optimal staining

  • Incubate at 4°C overnight for best results with polyclonal antibodies

• Expected staining pattern:

  • Look for specific staining of nucleoli in select hepatocytes, which is the characteristic pattern for SLC25A47

  • Use positive controls (normal liver tissue) and negative controls (antibody diluent only)

• Counterstaining and imaging:

  • Use hematoxylin for nuclear counterstaining

  • Employ high-resolution imaging to capture the subcellular localization pattern

This protocol enables reliable detection of SLC25A47 in liver tissues for research applications.

How can researchers optimize Western blot protocols for detecting SLC25A47?

When optimizing Western blot protocols for SLC25A47 detection:

• Sample preparation considerations:

  • Use specialized mitochondrial extraction buffers to ensure intact protein recovery

  • Include protease inhibitors to prevent degradation

  • Consider enriching for mitochondrial fractions to improve detection sensitivity

• Gel electrophoresis parameters:

  • Use 10-12% SDS-PAGE gels for optimal separation around the expected size range (22-33 kDa)

  • Include molecular weight markers that cover the 20-40 kDa range for accurate size determination

• Transfer and detection optimization:

  • Optimize transfer conditions (time, voltage) for proteins in the 20-35 kDa range

  • Use PVDF membranes for better protein retention

  • For preliminary experiments, test an antibody concentration of 0.5 μg/mL

• Addressing molecular weight discrepancies:

  • Run positive controls from liver tissue lysates where the protein is known to be expressed

  • Consider the possibility of detecting the approximately 22 kDa band rather than the expected 33.4 kDa band

  • Validate specificity using tissues from knockout models when available

These optimizations will help improve detection reliability when working with SLC25A47 antibodies in Western blot applications.

What are the best approaches for validating the specificity of SLC25A47 antibodies?

Validating antibody specificity is crucial for reliable research outcomes:

• Genetic validation approaches:

  • Compare staining patterns between wild-type tissues and those from Slc25a47-knockout mice

  • Use overexpression models (e.g., adenovirus-mediated Slc25a47 overexpression) as positive controls

• Peptide competition assays:

  • Pre-incubate the antibody with the immunizing peptide (e.g., KSRLQADGQGQRR for antibodies targeting AA 242-254)

  • Observe elimination or significant reduction of signal in the presence of the specific peptide

• Cross-validation with multiple antibodies:

  • Use antibodies from different suppliers or those targeting different epitopes

  • Compare staining patterns and signal specificity between antibodies

• Correlation with mRNA expression:

  • Verify protein detection results against known tissue expression patterns (predominantly liver)

  • Consider dual staining with mRNA probes (ISH) and antibodies in the same tissue section

These validation steps ensure that experimental results accurately reflect SLC25A47 biology rather than non-specific interactions.

How can SLC25A47 antibodies be applied in metabolic disease research?

SLC25A47 antibodies offer valuable tools for investigating metabolic disorders:

• Lipid metabolism studies:

  • Use antibodies to correlate SLC25A47 expression with lipid accumulation in liver tissues

  • Compare expression levels between normal, steatotic, and NASH liver samples

  • Quantify changes in response to interventions that affect lipid metabolism

• Mitochondrial dysfunction analysis:

  • Combine SLC25A47 immunostaining with markers of mitochondrial function

  • Correlate expression with oxygen consumption rate (OCR) measurements in cellular models

  • Investigate relationships with key metabolic regulators like AMPK and SIRT3

• Therapeutic target validation:

  • Monitor changes in SLC25A47 expression in response to metabolic interventions

  • Use antibodies to validate in vivo effects of treatments targeting mitochondrial function

• Biomarker development:

  • Assess correlation between SLC25A47 expression patterns and disease progression

  • Evaluate potential as a diagnostic or prognostic marker in liver diseases

These applications highlight the translational value of SLC25A47 antibodies in metabolic research.

What approaches can be used to study the relationship between SLC25A47 and NAD+ metabolism?

The emerging role of SLC25A47 as a mitochondrial NAD+ transporter suggests several research approaches:

• Transport assays with antibody validation:

  • Measure NAD+ uptake in isolated mitochondria while confirming SLC25A47 expression levels

  • Compare uptake between wild-type, Slc25a47-KO, and Slc25a47-overexpressing models

  • Use antibodies to confirm protein expression in functional studies

• Metabolic pathway analysis:

  • Investigate how SLC25A47 expression correlates with NAD+/NADH ratios in cellular compartments

  • Study the impact on SIRT3 activity and subsequent effects on metabolic enzyme regulation

  • Use isotope tracing experiments to track NAD+ metabolism in conjunction with antibody-based detection

• Regulatory network characterization:

  • Examine how SLC25A47-mediated NAD+ transport affects AMPK activation

  • Study the bidirectional relationship between SIRT3 and AMPK pathway components

• Therapeutic manipulation:

  • Test NAD+ precursors' effectiveness in models with variable SLC25A47 expression

  • Monitor changes in SLC25A47 expression in response to interventions affecting NAD+ metabolism

These approaches provide comprehensive insights into SLC25A47's role in mitochondrial NAD+ homeostasis.

How can researchers apply multiplexed immunodetection techniques with SLC25A47 antibodies?

Multiplexed detection enables more comprehensive analysis of SLC25A47 in the context of interacting proteins:

• Co-immunoprecipitation approaches:

  • Use optimized protocols for co-IP of Flag-tagged Slc25a47 to identify interaction partners

  • Verify interactions with components of metabolic regulatory pathways

• Multi-color immunofluorescence:

  • Combine SLC25A47 antibodies with markers for:

    • Mitochondrial localization (e.g., TOM20, COX IV)

    • Lipid metabolism regulators (e.g., SREBPs)

    • Cell proliferation markers (e.g., Ki67) for cancer studies

• Tissue microarray analysis:

  • Develop quantitative scoring systems for SLC25A47 expression in multiple samples

  • Correlate with clinical parameters and disease progression markers

• Live-cell imaging considerations:

  • For studies requiring real-time analysis, consider fluorescently-tagged SLC25A47 constructs

  • Validate localization patterns against antibody staining in fixed cells

These multiplexed approaches provide richer contextual information about SLC25A47 function in complex biological systems.

What strategies can address challenges in detecting low-abundance SLC25A47 in non-liver tissues?

While SLC25A47 is predominantly expressed in the liver , detecting it in other tissues presents challenges:

• Signal amplification methods:

  • Employ tyramide signal amplification (TSA) to enhance sensitivity for IHC applications

  • Consider using more sensitive detection systems like chemiluminescent substrates for Western blotting

• Sample enrichment strategies:

  • Perform subcellular fractionation to concentrate mitochondrial proteins

  • Use immunoprecipitation prior to Western blotting for low-abundance samples

• Alternative detection platforms:

  • Consider proximity ligation assay (PLA) for detecting protein-protein interactions involving SLC25A47

  • Explore mass spectrometry-based targeted proteomics for quantitative analysis

• Validation considerations:

  • Include appropriate positive controls (liver tissue) in experiments

  • Verify antibody sensitivity limits using dilution series of recombinant protein

These strategies help overcome sensitivity limitations when investigating SLC25A47 expression beyond its primary site in the liver.